IRF4 controls immune and metabolic signaling with functional effects on the crosstalk between B and T cells 2741
Abstract Description A subset of follicular lymphoma patients has an early relapse with a poor outcome. We showed that this unfavorable group displays increased expression of IRF4, dysregulated immune signaling and an immunosuppressive microenvironment. However, little is known on the molecular mechanisms whereby IRF4 controls the crosstalk between B and T cells. To this aim, we leveraged Cγ1cre;irf4fl/fl mice that yield conditional deletion of irf4 (cKO) in germinal center B cells (GCB). After 10 days of immunization, cKO GCB showed significant increase of HLA-DR and CD40 expression, a skewed LZ:DZ ratio towards increased DZ, and suppression of plasma cells compared to WT. Upon irf4 deletion, we also found a significant increase of total CD4 and TFH cells and a decrease in Treg cells. To test if this effect was antigen-dependent, we cocultured sorted GCB from NP-OVA-immunized cKO and WT mice with CSFE-labeled OVA-specific OT-II CD4 T cells at a ratio of 2:1 for 5 days. We observed increased antigen specific proliferation of CD4 T cells with cKO GCB compared to WT. We then performed seahorse assay and mass spectrometry of the same GCB to define if IRF4-dependent B cell metabolic reprogramming influences immune responses. GCB cKO had lower glycolytic ECAR and increased intracellular glucose and non-essential amino acids than WT cells, suggesting a metabolic shift from glycolysis to the TCA cycle. Thus, IRF4 controls immune and metabolic signaling with functional effects on the B-T cell crosstalk. Funding Sources NCI K08CA279652, LRF Clinical Investigator Award (CDA 1020588), the Gerstner Family Career Development Award, the ASH Junior Faculty Scholar Award. Topic Categories Tumor Immunology: Cellular Responses and Tumor Microevironment (TIME)
Authors
- Vaishali Bhardwaj (ORCID: https://orcid.org/0000-0002-2880-0187)
- Harinder Singh (ORCID: https://orcid.org/0000-0002-6330-8526)
- Patrizia Mondello (ORCID: https://orcid.org/0000-0002-0355-3757)
- Christine Hachfeld
- Stephen M. Ansell (ORCID: https://orcid.org/0000-0003-1244-6758)
- Megan Moore Weivoda (ORCID: https://orcid.org/0000-0003-0240-0123)
- Xinyi Tang (ORCID: https://orcid.org/0000-0002-1889-4562)
- Mark J. Shlomchik (ORCID: https://orcid.org/0000-0002-2152-0959)
- Prithviraj Mukherjee (ORCID: https://orcid.org/0009-0007-7779-8814)
- Nicholas A. Graham (ORCID: https://orcid.org/0000-0002-6811-1941)
- Zhi-Zhang Yang
- J. V. Landau
Institutions
- WinnMed (US)
- University of California San Diego (US)
- University of Pittsburgh Medical Center (US)
Publication Details
- Journal
- The Journal of Immunology
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1093/jimmun/vkaf283.627
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00